Roche's hopes of gaining EU approval for its new multiple sclerosis therapy, Ocrevus (ocrelizumab), before the end of the year are looking weak after the product failed to receive a positive opinion at the latest meeting of the CHMP last week.
Ocrevus, which was the first MS drug to get a label that included its use in primary progressive disease, has...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
